FORA Capital LLC bought a new stake in DaVita Inc. (NYSE:DVA – Get Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,186 shares of the company’s stock, valued at approximately $251,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Johnson Financial Group Inc. bought a new stake in DaVita during the fourth quarter worth $27,000. CWM LLC grew its holdings in DaVita by 154.1% during the 1st quarter. CWM LLC now owns 432 shares of the company’s stock worth $49,000 after acquiring an additional 262 shares during the period. FourThought Financial LLC grew its holdings in DaVita by 49.6% during the 1st quarter. FourThought Financial LLC now owns 510 shares of the company’s stock worth $56,000 after acquiring an additional 169 shares during the period. Quent Capital LLC bought a new position in shares of DaVita during the 4th quarter worth about $118,000. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of DaVita by 847.8% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock worth $123,000 after purchasing an additional 975 shares in the last quarter. Institutional investors and hedge funds own 88.47% of the company’s stock.
DaVita Stock Up 1.0 %
DVA opened at $87.80 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.37 and a debt-to-equity ratio of 11.69. DaVita Inc. has a 1-year low of $74.97 and a 1-year high of $133.88. The company has a market capitalization of $8.02 billion, a PE ratio of 10.89, a PEG ratio of 1.38 and a beta of 1.16. The firm’s 50 day simple moving average is $86.29 and its two-hundred day simple moving average is $99.58.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Barclays dropped their target price on shares of DaVita from $128.00 to $103.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of DaVita from $150.00 to $97.00 and set a “buy” rating for the company in a research note on Tuesday, August 2nd. Truist Financial cut their price target on shares of DaVita from $110.00 to $90.00 and set a “hold” rating for the company in a report on Wednesday, June 22nd. Cowen dropped their price objective on shares of DaVita to $95.00 in a report on Tuesday, August 9th. Finally, UBS Group lifted their price objective on shares of DaVita from $106.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, August 19th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $106.00.
Insider Transactions at DaVita
In related news, COO Michael David Staffieri acquired 20,000 shares of the stock in a transaction on Thursday, June 23rd. The stock was bought at an average cost of $77.70 per share, with a total value of $1,554,000.00. Following the transaction, the chief operating officer now directly owns 61,190 shares in the company, valued at $4,754,463. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.00% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.